While glioblastoma is currently categorized as either isocitrate dehydrogenase wild type or isocitrate dehydrogenase mutant, the identification of subtypes within these two categories [46,78,79,80], including levels of MT1-MMP expression, may provide insight into patient-specific treatment strategies. This evidence concerns the gene IDH3A and glioblastoma.